To read the full story, subscribe or sign in.

Otsuka says IgAN, too, with phase III sibeprenlimab data

Oct. 29, 2024

Visterra Inc., a subsidiary of Otsuka Pharmaceutical Co. Ltd., reported positive top-line data from the ongoing Visionary phase III study of sibeprenlimab, an anti-APRIL monoclonal antibody for immunoglobulin A nephropathy (IgAN).

BioWorld Asia Clinical Immune Monoclonal antibody Asia-Pacific

Today's news in brief

BioWorld

BioWorld briefs for Jan. 30, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 30, 2025

Vilastobart set apart? Xilio phase II combo performs in CRC

BioWorld

“The [colorectal cancer field is moving, and thankfully it’s moving quickly,” said Marwan Fakih, gastrointestinal specialist at City of Hope, speaking about...

Novo weight-loss data roll out; Veru ‘leans’ in

BioWorld

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line...

Appointments and advancements for Jan. 29, 2025

BioWorld

New hires and promotions in the biopharma industry, including: Allogene, Alumis, Beximco, Clarametyx, Commit, Concerto, OS Therapies, Precision, Roche, Scholar Rock.